Failed treatment of amelanotic lentigo maligna with imiquimod followed by pigment production
Department of Medicine, Division of Dermatology
Letter to the Editor
Administration, Topical; Aminoquinolines; Biopsy, Needle; Female; Follow-Up Studies; Humans; Hutchinson's Melanotic Freckle; Immunohistochemistry; Melanoma, Amelanotic; Middle Aged; Neoplasm Recurrence, Local; Nose; Risk Assessment; Skin Neoplasms; Treatment Outcome
Dermatology | Skin and Connective Tissue Diseases
A melanotic lentigo maligna (ALM) represents a small subset of lentigo maligna (LM) that lacks pigment. At least 2 cases of ALM responsive to imiquimod therapy with short-term follow-up have been reported. We report herein a case of ALM that failed to respond to imiquimod treatment. Furthermore, after therapy was initiated, the ALM began to produce pigment and transformed to LM.
DOI of Published Version
Martires KJ, Capaldi L, Pattee SF, Maloney ME, Bordeaux JS. Failed treatment of amelanotic lentigo maligna with imiquimod followed by pigment production. Arch Dermatol. 2010 Sep;146(9):1047-8. doi: 10.1001/archdermatol.2010.237.
Archives of dermatology
Martires KJ, Capaldi L, Pattee SF, Maloney ME, Bordeaux JS. (2010). Failed treatment of amelanotic lentigo maligna with imiquimod followed by pigment production. Dermatology Publications. https://doi.org/10.1001/archdermatol.2010.237. Retrieved from https://escholarship.umassmed.edu/derm_pubs/30